Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

M González Cao; S Viteri; C Garrán; Y Nieto; J Aristu; M Ponz; S Martín Algarra

doi:10.1007/s12094-007-0023-6

Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

Clin Transl Oncol. 2007 Feb;9(2):119-20. doi: 10.1007/s12094-007-0023-6.

Authors

M González Cao¹, S Viteri, C Garrán, Y Nieto, J Aristu, M Ponz, S Martín Algarra

Affiliation

¹ Oncology Department, Clínica Universitaria de Navarra, C/Pio XII s/n, 31008 Pamplona, Spain. mgocao@unav.es

PMID: 17329225
DOI: 10.1007/s12094-007-0023-6

Abstract

We report here a taxol-bevacizumab-responsive metastatic melanoma case. Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.

MeSH terms

Adult
Angiogenesis Inhibitors / adverse effects*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic / administration & dosage*
Bevacizumab
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Melanoma / drug therapy*
Paclitaxel / administration & dosage*
Remission Induction
Skin Neoplasms / drug therapy*

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic
Bevacizumab
Paclitaxel